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Background: Metabolic liver function can be measured by dynamic PET/CT with the radio-labelled
galactose-analogue 2-[18F]fluoro-2-deoxy-D-galactose (18F-FDGal) in terms of hepatic systemic clearance of
18F-FDGal (K, ml blood/ml liver tissue/min). The method requires arterial blood sampling from a radial artery
(arterial input function), and the aim of this study was to develop a method for extracting an image-derived,
non-invasive input function from a volume of interest (VOI).
Methods: Dynamic 18F-FDGal PET/CT data from 16 subjects without liver disease (healthy subjects) and 16 patients
with liver cirrhosis were included in the study. Five different input VOIs were tested: four in the abdominal aorta and
one in the left ventricle of the heart. Arterial input function from manual blood sampling was available for all subjects.
K*-values were calculated using time-activity curves (TACs) from each VOI as input and compared to the K-value
calculated using arterial blood samples as input. Each input VOI was tested on PET data reconstructed with
and without resolution modelling.
Results: All five image-derived input VOIs yielded K*-values that correlated significantly with K calculated
using arterial blood samples. Furthermore, TACs from two different VOIs yielded K*-values that did not statistically
deviate from K calculated using arterial blood samples. A semicircle drawn in the posterior part of the abdominal aorta
was the only VOI that was successful for both healthy subjects and patients as well as for PET data reconstructed with
and without resolution modelling.
Conclusions: Metabolic liver function using 18F-FDGal PET/CT can be measured without arterial blood samples by
using input data from a semicircle VOI drawn in the posterior part of the abdominal aorta.
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Dynamic PET/CT with the tracer 2-[18F]fluoro-2-deoxy-
D-galactose (18F-FDGal) enables in vivo measurement of
metabolic liver function in terms of hepatic systemic
clearance of 18F-FDGal (K, ml blood/ml liver tissue/min)
[1-3]. In short, the procedure includes intravenous bolus
administration of 100 MBq 18F-FDGal in the beginning
of a 20-min dynamic PET recording of the liver with ar-
terial blood samples from a catheter in a radial artery. K
is then calculated using a kinetic model of irreversible* Correspondence: michael@pet.auh.dk
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unless otherwise stated.trapping of 18F-FDGal-1-phosphate in the liver using the
time-activity curve (TAC) from arterial blood (Artery-
TAC) as input function and the TAC from liver tissue
(Liver-TAC) as output function [1-3]. The use of single
arterial input concentration instead of the mixed porto-
arterial concentration to the liver was validated in pigs
[3], and the final protocol using 20-min PET recording
was validated in patients with cirrhosis and healthy
subjects [1,2]. The rate-limiting step in hepatic metabol-
ism of 18F-FDGal is phosphorylation of the tracer by
galactokinase to 18F-FDGal-1-phosphate. K of 18F-FDGal
is flow-independent and depends only on enzymatic
capacity, i.e., Vmax of galactokinase [1,2], and it thus
reflects metabolic function.l. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited. The Creative Commons Public Domain
/publicdomain/zero/1.0/) applies to the data made available in this article,
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images of metabolic liver function which was used to dem-
onstrate that patients with cirrhosis have a lower hepatic
metabolism of 18F-FDGal compared to healthy subjects in
addition to an increased variation in intrahepatic meta-
bolic function [1]. Evaluation of regional differences in
metabolic liver function has many potential applications;
it could for example be used to spare the best functioning
areas of the liver when planning stereotactic radiotherapy
of liver tumours [4].
We hypothesized that scan data from the abdominal
aorta or the left ventricle of the heart can replace arterial
blood sampling, and the aim of the present study was
to define an image-derived input-TAC to replace the
Artery-TAC for calculating K in dynamic 18F-FDGal
PET/CT studies of metabolic liver function. For this
purpose, input-TACs from different volumes of interest
(VOIs) in the abdominal aorta and left ventricle of the heart
were tested. Since image-derived input-TACs are prone to
errors caused by spill-over effects from surrounding tis-
sues which may be reduced using images with improved
spatial resolution provided by reconstruction algorithms
with resolution modelling (point spread function correc-
tion) [5], we applied each VOI to PET data reconstructed
with and without resolution modelling. Making 18F-FDGal
PET/CT of metabolic liver function a non-invasive pro-
cedure would spare the patient from the discomfort of
having a catheter inserted into the radial artery and reduce
the radiation burden of the technical staff. The method
would thus be safer, simpler, and more general applicable
for routine clinical use.
Methods
Data comprised raw data from two previously published
18F-FDGal PET studies: eight patients with cirrhosis [1]
and seven subjects with no parenchymal liver disease
(healthy subjects) [2]. In addition, unpublished data from
nine healthy subjects and eight patients with cirrhosis
were included. In total, 16 healthy subjects and 16
patients with cirrhosis were thus included in the study.
The study was approved by The Central Denmark
Region Committees on Health Research Ethics and
conducted in accordance with the Helsinki Declaration.
PET studies
All subjects were studied in supine position using the
same PET/CT camera, a 64-slice Siemens Biograph True-
point PET/CT camera (Siemens AG, Erlangen, Germany).
Before the PET recording, a topogram of the upper abdo-
men was performed for optimal positioning of the liver
within the 21.6-cm transaxial field-of-view of the PET
camera followed by a low-dose CT scan (50 effective mAs
with CARE Dose4D (Siemens Healthcare, Erlangen,
Germany), 120 kV, pitch 0.8, slice thickness 5 mm) fordefinition of anatomical structures and attenuation correc-
tion of PET data. A bolus of 100 MBq of 18F-FDGal in 10
ml saline was administered intravenously during the initial
15 to 20 s of a dynamic PET recording (list-mode). In PET
recordings exceeding 20 min, only measurements up to 20
min were used in the present study since this is now the
standard protocol [1-3]. 18F-FDGal was produced in our
own radiochemistry laboratory (radiochemical purity ≥
97%) [6].
All subjects had an Artflon catheter (Artflon, Ohmeda,
Swindon, UK) placed percutaneously in a radial artery.
During the PET recording, arterial blood samples (0.5 ml)
were manually collected for determination of 18F-FDGal
blood concentrations (kBq/ml) using a well counter (Packard
Instruments, Meriden, CT, USA) and corrected for radio-
activity decay back to start of the scan.
Reconstruction of PET data
Data were reconstructed using two different methods:
without resolution modelling (336 matrix, voxel size 2 ×
2 × 2 mm3, 6 iterations, 21 subsets, 2-mm Gaussian filter,
separate prompts/randoms) and with resolution modelling
(336 matrix, voxel size 2 × 2 × 2 mm3, 4 iterations, 21 sub-
sets, 2-mm Gaussian filter, separate prompts/randoms).
Measurements were corrected for radioactivity decay back
to start of the scan. Time-frame structure was 18 × 5,
15 × 10, 4 × 30, 4 × 60, and 2 × 300 s, total 20 min.
Image analysis
Liver-VOI
Using fused PET/CT images, regions of interest (ROIs)
were drawn in successive image planes in the paren-
chyma of the right liver lobe avoiding large blood vessels
and summed into a volume of interest (Liver-VOI). The
same VOI was used to generate a liver time-activity
curve (Liver-TAC; liver activity concentration in kBq/ml
liver tissue vs. time in minutes) for both reconstruction
methods.
Aorta-VOI
Four different VOIs in the abdominal aorta were tested;
for all four VOIs, ROIs were drawn in adjacent transaxial
planes starting 3 planes below the diaphragm (6 mm) and
continued for 40 planes in the caudal direction (total
length, 8 cm). The ROIs were summed into an Aorta-VOI,
and an Aorta-TAC (blood concentration in kBq/ml blood
vs. time in minutes) was generated for both reconstruction
methods. The four Aorta-VOIs were defined as (Figure 1):
 Aorta-VOI-1: A semicircle drawn in the posterior
half of the aorta with the straight line (length one
third of the total diameter of the aorta) going
through the centre of the vessel. Average volume
was 2.95 ml (range, 2.03 to 4.21 ml).
Figure 1 Illustration of the five VOIs tested shown in a transaxial
plane. Aorta-VOI-1 (A), Aorta-VOI-2 (B), Aorta-VOI-3 (C), Aorta-VOI-4
(D), and Ventricle-VOI (E).
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the aorta with a diameter of one third of the
diameter of the aorta. Average volume was 4.75 ml
(range, 3.04 to 6.23 ml).
 Aorta-VOI-3: A semicircle drawn in the posterior
half of the aorta with a diameter equal to that of the
aorta and with the straight line going through the
centre of the vessel. Average volume was 10.23 ml
(range, 6.17 to 15.59 ml).
 Aorta-VOI-4: A circular ROI including the entire
aorta in each plane included in the VOI. Average
volume was 32.1 ml (range, 21.62 to 45.78 ml).
Ventricle-VOI
For the VOI in the left ventricle of the heart (Ventricle-
VOI), circular ROIs were drawn in four to six adjacent
transaxial planes (Figure 1). Average volume was 1.88 ml
(range, 0.89 to 5.65 ml).
Data analysis
Hepatic systemic clearance of 18F-FDGal (ml blood/ml
liver tissue/min) was calculated according to the Gjedde-
Patlak representation of data [7,8] as validated in previous
studies [1-3]. In short, the hepatic systemic clearance is
defined as the slope of the asymptote fitted to the linear
part of the data representation 6 to 20 min after tracer ad-
ministration [1-3,7,8]. The Liver-TAC was used as output
function, and the hepatic systemic clearance of 18F-FDGal
was calculated for each non-invasive input function (K*)
and compared to the value calculated using the Artery-
TAC (K) which was used as reference value.
Statistics
Correlation between K* and K was tested by the Pearson
product–moment correlation coefficient, r, and a p value <
0.05 was interpreted to indicate a statistically signifi-
cant correlation. Mean relative deviations of K* from
K, i.e., (K* − K)/K, were tested by a one-sample t-test,
and deviations with a p value < 0.05 were considered
statistically significant.
Results
The correlation between K* and K was significant for all
five VOIs using both reconstruction methods and for
both healthy subjects (Table 1) and patients with cirrho-
sis (Table 2) (p < 0.01 for all combinations).
For healthy subjects, the mean relative deviation of K*
from K was not significantly different from zero for any
of the five VOIs or two reconstruction methods except
for Aorta-VOI-2 without resolution modelling (p = 0.04)
(Table 1). Based on mean relative deviation, Aorta-VOI-1,
Aorta-VOI-3, and Aorta-VOI-4 performed equally well
and were only slightly more accurate than Ventricle-VOI
(Table 1).
Table 1 Healthy subjects (functional 18F-FDGal PET/CT of the liver using image-derived non-invasive input function)
VOI Without resolution modelling With resolution modelling
Correlation between
K* and K, r
Relative deviation of
K* from K
Correlation between
K* and K, r
Relative deviation of
K* from K
Aorta-VOI-1 0.878 −0.044 ± 0.039 0.866 0.016 ± 0.061
(p < 0.01) (p = 0.28) (p < 0.01) (p = 0.79)
Aorta-VOI-2 0.914 −0.076 ± 0.033 0.889 −0.047 ± 0.050
(p < 0.01) (p < 0.05) (p < 0.01) (p = 0.37)
Aorta-VOI-3 0.858 0.071 ± 0.061 0.832 0.143 ± 0.091
(p < 0.01) (p = 0.27) (p < 0.01) (p = 0.14)
Aorta-VOI-4 0.882 0.066 ± 0.057 0.848 0.142 ± 0.088
(p < 0.01) (p = 0.26) (p < 0.01) (p = 0.13)
Ventricle-VOI 0.819 0.141 ± 0.088 0.904 0.044 ± 0.046
(p < 0.01) (p = 0.13) (p < 0.01) (p = 0.35)
K* = hepatic systemic clearance of 18F-FDGal (ml blood/ml liver tissue/min) estimated using image-derived input function; K = hepatic systemic clearance of
18F-FDGal (ml blood/ml liver tissue/min) estimated using time-activity curve from manual blood sampling from the radial artery; VOI = volume of interest
(see Figure 1 for details on each VOI definition). r = Pearson correlation coefficient for correlation between individual pairs of K* and K; p < 0.05 is considered
to indicate statistically significant correlation. Relative deviation of K* from K is presented as mean ± SEM; mean deviation with p < 0.05 is considered statistically
significantly different from zero.
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of K* from K was not significantly different from zero for
Aorta-VOI-1 and Aorta-VOI-2 for any of the two recon-
struction methods (p > 0.05) (Table 2). For Aorta-VOI-3,
Aorta-VOI-4, and Ventricle-VOI, the mean relative devi-
ation was significantly different from zero using both re-
construction methods (Table 2).
Discussion
This study demonstrates that arterial blood sampling can
be successfully replaced by an image-derived TAC as input
function when calculating metabolic liver function fromTable 2 Patients with cirrhosis (functional 18F-FDGal PET/CT o
function)
VOI Without resolution modelling
Correlation between
K* and K, r
Relative deviatio
K* from K
Aorta-VOI-1 0.911 0.059 ± 0.040
(p < 0.01) (p = 0.16)
Aorta-VOI-2 0.904 0.044 ± 0.041
(p < 0.01) (p = 0.37)
Aorta-VOI-3 0.897 0.162 ± 0.049
(p < 0.01) (p < 0.01)
Aorta-VOI-4 0.874 0.169 ± 0.055
(p < 0.01) (p < 0.01)
Ventricle-VOI 0.872 0.203 ± 0.058
(p < 0.01) (p < 0.01)
K* = hepatic systemic clearance of 18F-FDGal (ml blood/ml liver tissue/min) estimate
18F-FDGal (ml blood/ml liver tissue/min) estimated using time-activity curve from man
for details on each VOI definition). r = Pearson correlation coefficient for correlation be
significant correlation. Relative deviation of K* from K is presented as mean ± SEM; me
from zero.dynamic 18F-FDGal PET/CT. All five image-derived input
VOIs yielded K*-values that correlated with the reference
value, i.e., K calculated using the Artery-TAC from arterial
blood sampling but Aorta-VOI-1 was the only input VOI
that yielded results not statistically different from the ref-
erence in both healthy subjects and patients with cirrhosis
using both reconstruction methods. Figure 2A, B shows
the correlation between K* and K for Aorta-VOI-1, and,
as shown in the Bland Altman plots in Figure 2C, D, there
were no systematic deviations for high or low values.
The healthy liver accumulates more 18F-FDGal than a cir-
rhotic liver [1,2], and the reason why Aorta-VOI-2 failedf the liver using image-derived non-invasive input
With resolution modelling
n of Correlation between
K* and K, r
Relative deviation of
K* from K
0.924 0.078 ± 0.039
(p < 0.01) (p = 0.07)
0.919 0.051 ± 0.037
(p < 0.01) (p = 0.19)
0.893 0.210 ± 0.052
(p < 0.01) (p < 0.01)
0.878 0.223 ± 0.057
(p < 0.01) (p < 0.01)
0.895 0.173 ± 0.050
(p < 0.01) (p < 0.01)
d using image-derived input function; K = hepatic systemic clearance of
ual blood sampling from the radial artery; VOI = volume of interest (see Figure 1
tween individual pairs of K* and K; p < 0.05 is considered to indicate statistically
an deviation with p < 0.05 is considered statistically significantly different
Figure 2 Correlation plots and Bland Altman plots for Aorta-VOI-1. Correlation between K* and K without resolution modelling (A) and with
resolution modelling (B). Bland Altman plot without resolution modelling (C) and with resolution modelling (D). Closed circles (●) are
healthy subjects, and open circles (○) are patients with cirrhosis.
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healthy subjects may be due to spill-over from the liver
in the anterior part of the aorta which was not included
in Aorta-VOI-1 (Figure 1). This would make the input
function too high, leading to an underestimation of K*
(i.e., K* < K), which agrees with the observed deviation
(Table 1). Since patients with cirrhosis have decreased
metabolic liver function [1], the spill-over from the liver is
expected to be lower which might explain why both re-
construction methods were successful for both Aorta-
VOI-1 and Aorta-VOI-2 in patients with cirrhosis.
Both Aorta-VOI-3 and Aorta-VOI-4 yielded K* values
that deviated significantly from K in patients with cir-
rhosis for both reconstruction methods. The close rela-
tion of these two VOIs to the edge of the aorta could
explain this since most of the aorta is surrounded by
structures with low radioactivity which could lead to
an underestimation of the image-derived TAC when
compared to the Artery-TAC. The calculated K* would
accordingly be higher than K, which was true for all four
cases (relative deviation > 0.162, Table 1). On the otherhand, no significant deviation was present in healthy sub-
jects. Spill-over from the hot liver might have increased
the image-derived input in these VOIs, counter-acting the
effect of surrounding structures with low radioactivity.
The Ventricle-VOI yielded K* values that were higher
than K, but the difference was only statistically significant
in patients with cirrhosis. The Ventricle-VOI is subject to
both respiratory and cardiac movement as well as spill-
over from the liver. However, in the present case, the over-
estimated K* values indicate inclusion of cold areas in the
VOI (such as the myocardial wall and surrounding lung
tissue) due to the respiratory and cardiac movements. We
included the Ventricle-VOI in the present study because
ventricle-VOIs sometimes are used to derive input con-
centrations in other studies, but in the present study, it
failed to provide a good input function, probably due to
the reasons discussed above. In addition, only the lower
part of the left ventricle of the heart was included in the
field of view because the main focus of the investigations
was the liver. This may have contributed to a relative poor
definition of the Ventricle-VOI.
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PET/CT is creation of three-dimensional parametric im-
ages which makes it possible to study intrahepatic vari-
ation in metabolic capacity [1,2]. This can for example
be used to spare well-functioning areas of the liver when
treating liver tumours with stereotactic radiotherapy [4].
The simplification of the method by avoiding arterial
catheterization makes it safer and more attractive to re-
peat over time when monitoring metabolic liver function
in patients with cirrhosis, following different treatments of
diseases of the liver, or for scientific purposes.
Because 18F-FDGal is very specifically taken up and ac-
cumulated in the liver, spill-over from other organs was
not a major concern in the present case. However, for
other tracers, such as the glucose tracer 2-[18F]fluoro-2-
deoxy-D-glucose (18F-FDG) which is taken up in most
tissues, another VOI definition may be required. One
method for defining an image-derived input function for
18F-FDG of the liver was published some years ago with a
circular Aorta-VOI drawn in the middle of the abdominal
aorta for 18F-FDG PET of liver tumours using a dedicated
PET camera [9]. It is recommended that an image-derived
input function is tested individually for specific PET
tracers and different reconstruction methods before pro-
ceeding to routine use of the method.
Conclusions
We have defined an image-derived input function in
terms of a semicircle drawn in the posterior part of the
abdominal aorta that could replace arterial blood sampling
successfully for quantification of metabolic liver function
using 18F-FDGal PET/CT. This makes the method safer,
simpler, and more generally applicable for routine clinical
and scientific use.
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